Nicotinic receptor mechanisms in neuropsychiatric disorders: Therapeutic implications

Primary Psychiatry

Volumn 17, Issue 1, 2010, Pages 35-41

  Bacher, Ingrid ^a   Rabin, Rachel ^b   Woznica, Andrea ^b   Sacco, Kristi A ^c   George, Tony P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CAMH ^*  (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1 AZA BICYCLO[2.2.2]OCT 3 YL)CARBAMIC ACID 1 (2 FLUORO PHENYL)ETHYL ESTER; 1 (5 CHLORO 2 HYDROXY PHENYL) 3 (2 CHLORO 5 TRIFLUOROMETHYL PHENYL)UREA; 3 (2,4 DIMETHOXYBENZYLIDENE) 3,4,5,6 TETRAHYDRO 2,3' BIPYRIDINE; 3 [(2,4 DIMETHOXY)BENZYLIDENE]ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; ALTINICLINE; AMFEBUTAMONE; CLOZAPINE; DONEPEZIL; FLUOXETINE; HALOPERIDOL; JN 403; MECAMYLAMINE; MEMANTINE; METHYLPHENIDATE; NICOTINE; NICOTINE PATCH; NICOTINIC AGENT; NICOTINIC RECEPTOR; PHYSOSTIGMINE; RIVASTIGMINE; SIB 5008Y; UNCLASSIFIED DRUG; VARENICLINE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; AUTISM; CLINICAL TRIAL; DEMENTIA; DRUG INHIBITION; DRUG MECHANISM; DYSKINESIA; EPILEPSY; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NEUROPROTECTION; NONHUMAN; PAIN; PARKINSON DISEASE; PSYCHOPATHY; REVIEW; SCHIZOPHRENIA; SENSORY DYSFUNCTION; SINGLE DRUG DOSE;

EID: 75449119504     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol. 1995;57:521-546.
2. Brody A, Mandelkern, MA, Jarvik, ME, et al. Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol Psychiatry. 2004;55(1):77-84.
3. Picciotto M, Addy, NA, Mineur, YS, Brunzell, DH. It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol. 2008;84(4):329-342.
4. Mansvelder H, McGehee, DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol. 2002;53(4):606-617.
5. McGehee D, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 1995;269(5231):1692-1696.
6. Pich E, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 1997;275(5296):83-86.
7. Morisano D, Bacher I, Audrain-McGovern J, George TP. Mechanisms Underlying the Co-morbidity of Tobacco Use in Mental Health and Addictive Disorders. Can J Psychiatry. 2009;54(6):356-367.
8. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106-123.
9. Hitsman B, Moss TG, Montoya ID, George T.. Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry. 2009;54(6):368-378.
10. Freedman R. Schizophrenia. N Engl J Med. 2003;349(18):1738-1749.
11. Breese C, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology. 2000;23(4):351-364.
12. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38(1):22-33.
13. Martin-Ruiz C, Haroutunian VH, Long P, et al. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2003;54(11):1222-1233.
14. De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatr Scand. 2006;114(3):211-215.
15. Gault J, Hopkins J, Berger R, et al. Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. Am J Med Genet B Neuropsychiatr Genet. 2003;123(1):39-49.
16. Leonard S, Gault J, Hopkins J, et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry. 2002;59(12):1085- 1096.
17. Mathew S, Law AJ, Lipska BK, et al. Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum Mol Genet. 2007;16(23):2921-2932.
18. Blaveri E, Kalsi G, Lawrence J, et al. Genetic association studies of schizophrenia using the 8p21-22 genes: prepronociceptin (PNOC), neuronal nicotinic cholinergic receptor alpha polypeptide 2 (CHRNA2) and arylamine N-acetyltransferase 1 (NAT1). Eur J Hum Genet. 2001;6:469-472.
19. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 1997;11(2):123-131.
20. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry. 1998;155(11):1490-1501.
21. Dépatie L, O'Driscoll GA, Holahan AL, Atkinson V, Thavundayil JX, Kin NN, Lal S. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacol. 2002;27(6):1056-1070.
22. George T, Vessicchio JC, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacol. 2002;26(1):75-85.
23. Kem W, Mahnir VM, Prokai L, et al. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol. 2004;65(1):56-67.
24. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63(6):630-638.
25. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165(8):1040- 1047.
26. Feuerbach D, Lingenhoehl K, Olpe HR, et al. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology. 2009;56(1):254-263.
27. Goff D, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149(9):1189-1194.
28. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev. 2005;29(6):1021-1034.
29. McEvoy J, Brown S. Smoking in first-episode patients with schizophrenia. Am J Psychiatry. 1999;156(7):1120-1121.
30. Green AI. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. J Clin Psychiatry. 2006;67(suppl 7):31-37.
31. George TP, Sernyak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 1995;56(8):344-346.
32. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
33. George TP, Vessicchio J, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26(1):75-85.
34. Sacco K, Termine A, Seyal A, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry. 2005;62(6):649-659.
35. Evins A, Culhane MA, Alpert JE, et al. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol. 2008;28(6):660-666.
36. First M, Spitzer R, Williams J, et al. Structured Clinical Interview for DSM-IV-Non-Patient Edition (SCIDNP, Version 1.0). Washington, DC: American Psychiatric Press; 1995.
37. Janowsky D, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 1972;2(7778):632-635.
38. Janowsky D, el-Yousef MK, Davis JM, Hubbard B, Sekerke HJ. Cholinergic reversal of manic symptoms. Lancet. 1972;1(7762):1236-1237.
39. Shytle RD SA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry. 2002;7(6):525-535.
40. Caldarone B, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry. 2004;56(9):657-664.
41. Rabenstein R, Caldarone BJ, Picciotto MR. The nicotinic antagonist mecamylamine has antidepressantlike effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology. 2006;189(3):395-401.
42. George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol. 2008;28(3):340-344.
43. Shytle R, Silver AA, Sheehan KH, Sheehan DV, Sanber, PR. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety. 2002;16(3):89-92.
44. McClernon F, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006189(1):125-133.
45. Salín-Pascual R, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996;57(9):387-389.
46. Spring B, Cook JW, Appelhans B, et al. Nicotine effects on affective response in depression-prone smokers. Psychopharmacology. 2008;196(3):461-471.
47. Cook J, Spring B, McChargue DE, et al. Influence of fluoxetine on positive and negative affect in a clinicbased smoking cessation trial. Psychopharmacology (Berl). 2004;173(1-2):153-159.
48. Kinnunen T, Korhonen T, Garvey AJ. Role of nicotine gum and pretreatment depressive symptoms in smoking cessation: twelve-month results of a randomized placebo controlled trial. Int J Psychiatry Med. 2008;38(3):373-389.
49. Mineur Y, Somenzi O, Picciotto MR. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology. 2007;52(5):1256- 1262.
50. Philip N, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry. 2009;70(7):1026-1031.
51. Shytle R, Silver AA, Sanberg PR. Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine). Biol Psychiatry. 2000;48(10):1028-1031
52. Lohoff F, Ferraro TN, McNabb L, et al. No association between common variations in the neuronal nicotinic acetylcholine receptor alpha2 subunit gene (CHRNA2) and bipolar I disorder. Psychiatry Res. 2005;135(3):171-177.
53. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57(11):1215-1220.
54. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord. 2005;9(2):384-391.
55. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
56. Achenbach TM, Howell CT, McConaughy SH, Stanger C. Six-year predictors of problems in a national sample: IV. Young adult signs of disturbance. J Am Acad Child Adolesc Psychiatry. 1998;37(7):718-727.
57. Millstein RB, Wilens TE, Biderman J, Spencer TJ. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Atten Disord. 1997;2(3):159-166.
58. Faraone SV, Biederman J, Monuteaux MC. Attention deficit hyperactivity disorder with bipolar disorder in girls: further evidence for a familial subtype? J Affect Disord. 2001;64(1):19-26.
59. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996;123(1):55-63.
60. McClernon FJ, Kollins SH, Lutz AM, et al. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. Psychopharmacology (Berl). 2008;197(1):95-105.
61. Potter AS, Newhouse PA. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2004;176(2):182-194.
62. Gehricke JG, Whalen CK, Jamner LD, Wigal TL, Steinhoff K. The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: a preliminary examination. Nicotine Tob Res. 2006;8(1):37-47.
63. Wilens TE, Biederman J, Spencer TJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1999;156(12):1931-1937.
64. Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry. 2006;59(11):1065-1070.
65. Schultz R. Developmental deficits in social perception in autism: the role of the amygdala and fusiform face area. Int J Dev Neurosci. 2005;23(2-3):125-141.
66. Perry EK, Lee ML, Martin-Ruiz CM, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry. 2001;158(7):1058-1066.
67. Ray M, Graham AJ, Lee M, et al. Neuronal nicotinic acetylcholine receptor subunits in autism: an immunohistochemical investigation in the thalamus. Neurobiol Dis. 2005;19(3):366-377.
68. Lee M, Martin-Ruiz C, Graham A, et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain. 2002;125(pt 7):1483-1495.
69. Lippiello PM. Nicotinic cholinergic antagonists: a novel approach for the treatment of autism. Med Hypotheses. 2006;66(5):985-990.
70. Hardan A, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002;12(3):237-241.
71. Hertzman M. Galantamine in the treatment of adult autism: a report of three clinical cases. Int J Psychiatry Med. 2003;33(4):395-398.
72. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16(5):621-629.
73. Chez M, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19(3):165-169.
74. Barker W, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203-212.
75. Delacourte A, Defossez A. Alzheimer's disease: tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J Neurol Sci. 1986;76(2-3):173-186.
76. Coyle J, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983;219(4589):1184-1190.
77. Warpman U, Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport. 1995;6(17):2419-2423.
78. Hogg RC, Bertrand D. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem Pharmacol. 2007;73(4):459-468.
79. Newhouse PA, Sunderland T, Tariot PN, et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl). 1988;95(2):171-175.
80. Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's Disease: pilot study on learning memory and safety. Pharmacol Biochem Behav. 1995;51(2-3):509-514.
81. White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (Berl). 1999;143(2):158-165.
82. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl). 1999;142(4):334-342.
83. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989;154:797-800.
84. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl). 1992;108(4):485-494.
85. van Duijn CM, Hofman A. Relation between nicotine intake and Alzheimer's disease. BMJ. 1991;302(6791):1491-1494.
86. Brenner DE, Kukull WA, van Belle G, et al. Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. Neurology. 1993;43(2):293-300.
87. Graves AB, van Duijn CM, Chandra V, et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20 suppl 2:S48-S57.
88. Aggarwal NT, Bienias JL, Bennett DA, et al. The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. Neuroepidemiology. 2006;26(3):140-146.
89. FDA Patient Safety News: Show #22, December 2003. New Class of Antibiotics for Skin Infections. Available at: www.accessdata.fda.gov/psn/ printer-full.cfm?id=26. Accessed December 9, 2009.
90. Buisson B, Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol. 1998;53(3):555-563.
91. Blanchard A, Guillemette G, Boulay G. Memantine potentiates agonist-induced Ca2+ responses in HEK 293 cells. Cell Physiol Biochem. 2008;22(1-4):205-214.
92. Kitagawa H, Takenouchi T, Azuma R, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology. 2003;28(3):542-551.
93. Timmermann D, Grønlien JH, Kohlhaas KL, et al. An allosteric modulator of the alpha7 nico-tinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007;323(1):294-307.
94. Glosser G. Neurobehavioral aspects of movement disorders. Neurol Clin. 2001;19(3):535-551.
95. Quik M, Bordia T, O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem Pharmacol. 2007;74(8):1224-1234.
96. Olanow C, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci. 1999;22:123-144.
97. Bohr I, Ray MA, McIntosh JM, et al. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [125I]aconotoxinMII in the striatum and thalamus. Exp Neurol. 2005;191(2):292-300.
98. Quik M, Bordia T, Forno L, McIntosh JM. Loss of a-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. J Neurochem. 2004;88(3):668-679.
99. Gotti C, Moretti M, Bohr I, et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease. Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis. 2006;23(2):481-489.
100. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55(3):259-272.
101. Hong DP, Fink AL, Uversky VN. Smoking and Parkinson's disease: does nicotine affect [alpha]-synuclein fibrillation? Biochim Biophys Acta. 2009;1794(2):282-290.
102. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004;27(9):561-568.
103. Gentry C, Lukas RJ. Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Disord. 2002;1(4):359-385.
104. Fagerström K, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl). 1994;116(1):117-119.
105. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn. 2000; 43(1-3):274-282.
106. Ishikawa A, Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J Neurol Sci. 1993;117(1-2):28-32.
107. Clemens P, Baron JA, Coffey D, Reeves A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology (Berl). 1995;117(2):253-256.
108. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD:a randomized, double-blind, placebo-controlled study. Neurology. 2001;57(6):1032-1035.
109. Ebersbach G, Stöck M, Müller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord. 1999;14(6):1011-1013.
110. Dickerson T, Janda KD. Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease. Proc Natl Acad Sci U S A. 2003;100(14):8182-8187.
111. Buccafusco J, Terry AV Jr. The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci. 2003;72(26):2931-2942.
112. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol. 2007;62(6):588-596.
113. Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology. 2006;66(3):408-410.
114. Yanagida T, Takeuchi H, Kitamura Y, et al. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci Res. 2008;62(4):254-261.
115. Sanberg P, Silver AA, Shytle RD, et al. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther. 1997;74(1):21-25.
116. McEvoy J, Allen TB. The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome. Curr Drug Targets CNS Neurol Disord. 2002;1(4):433-442.
117. Sanberg P, McConville BH, Fogelson HM, et al. Nicotine potentiates the effects of haloperidol in animals and patients with Tourette syndrome. Biomed Pharmacother. 1989;43(1):19-23.
118. McConville BJ, Sanberg PR, Fogelson MH, et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry. 1992;31(8):832-840.
119. Silver A, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001;62(9):707-714.
120. Arevalo E, Licamele WL, Bronheim S, Sonnenschein K. Nicotine gum in Tourette's disorder. Am J Psychiatry. 1992;149(3):417-418.
121. Shytle R, Silver AA, Philipp MK, McConville BJ, Sanberg PR. Transdermal nicotine for Tourette's Syndrome. Drug Dev Res. 1996;38(3-4):290-298.
122. Silver A, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR. Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(9):1103-1110.
123. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry. 2002;7(6):525-535.
124. Woznica AA, George TP. Exploiting nicotinic receptor mechanisms for the treatment of schizophrenia and depression. J Dual Diagnosis. In press.